IsoRay, Inc.(ISR) - 2026 Q1 - Quarterly Results

Filing Information This section provides core identification details for Perspective Therapeutics, Inc., including incorporation, executive offices, and registered securities Registrant Information This section details the registrant's legal and contact information, including its state of incorporation and principal executive offices - Perspective Therapeutics, Inc. is incorporated in Delaware[2] - Principal Executive Offices are located at 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121, with telephone (206) 676-0900[2] Registered Securities | Title of each class | Symbol(s) | Name of each exchange on which registered | | :------------------ | :-------- | :---------------------------------------- | | Common Stock, $0.001 par value | CATX | NYSE American LLC | Item 2.02 Results of Operations and Financial Condition The company announced updated interim clinical trial results and preliminary estimated financial information as of September 30, 2025, noting its unaudited nature - On October 20, 2025, the Company announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors[6] - Estimated cash, cash equivalents, and short-term investments as of September 30, 2025, were included in the press release and presentation[6] - All estimated financial information is preliminary, unaudited, and not reviewed by WithumSmith+Brown, PC[6][7] Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits This section details the filing of a Press Release and Presentation as exhibits to the 8-K report, providing further clinical and business updates - A Press Release and Presentation were issued on October 20, 2025, and filed as exhibits to this 8-K report[8] Exhibits Filed | Exhibit No. | Description | | :------------ | :-------------------------------------------------- | | 99.1 | Press Release dated October 20, 2025. | | 99.2 | Presentation. | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | Signatures The report was officially signed on October 20, 2025, by Johan (Thijs) Spoor, CEO of Perspective Therapeutics, Inc., affirming compliance - The report was signed by Johan (Thijs) Spoor, Chief Executive Officer of Perspective Therapeutics, Inc., on October 20, 2025[14]